Table 1.
Baseline characteristics.
Table 2.
Laboratory characteristics of SAVR and TAVI groups.
Table 3.
Occurrence of endpoints in SAVR and TAVI groups.
Table 4.
ROC analysis for prediction of endpoints in patients treated with TAVI.
Table 5.
ROC analysis for prediction of endpoints in patients treated with SAVR and TAVI.
Table 6.
Receiver operating characteristic (ROC) analysis for selected biomarkers.
Figure 1.
Risk assessment plot of the performance comparison between reference EuroSCORE model and new EuroSCORE+MDA model for combined safety endpoint at 30 days in TAVI+SAVR group (N = 42).
Prevalence – occurrence of endpoint in given group.
Figure 2.
Risk assessment plot of the performance comparison between reference EuroSCORE model and new EuroSCORE+MDA model for combined endpoint at 30 days in TAVI+SAVR group (N = 42).
Figure 3.
Risk assessment plot of the performance comparison between reference EuroSCORE model and new EuroSCORE+MDA model for combined safety endpoint at 30 days in TAVI group (N = 29).
Figure 4.
Risk assessment plot of the performance comparison between reference EuroSCORE model and new EuroSCORE+MDA model for combined endpoint at 30 days in TAVI group (N = 29).
Table 7.
Evaluation of additional benefit of biomarkers to clinical model (EuroSCORE) by net reclassification improvement (NRI) and the integrated discrimination improvement (IDI) for prediction of combined safety endpoint at 30 days and combined endpoint (0–365 days) in groups of patients treated by TAVI and by SAVR and TAVI.